Genmab A (GMAB) Raw Materials (2023 - 2025)

Genmab A's (GMAB) quarterly Raw Materials came in at $6.0 million in Q4 2025, up 500.0% YoY from $1.0 million in Q4 2024, and up 500.0% on a QoQ basis from $1.0 million in Q4 2024.

Genmab A (GMAB) Raw Materials (2023 - 2025) Analysis & Trends

Genmab A (GMAB) has 3 years of Raw Materials data on file, last reported at $6.0 million in Q4 2025.

  • Quarterly Raw Materials rose 500.0% year-over-year to $6.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.0 million (up 500.0% YoY) and the FY2025 annual result came in at $6.0 million, up 500.0% from the prior year.
  • Raw Materials rose to $6.0 million in Q4 2025, from $1.0 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $6.0 million in Q4 2025 to a low of $1.0 million in Q4 2024.
  • A 3-year average of $3.0 million and a median of $2.0 million in 2023 frame the typical range for Raw Materials.
  • Annual changes were most pronounced in 2024 — Raw Materials sank 50.0% — and 2025, when it soared 500.0%.
  • Tracing GMAB's Raw Materials over 3 years: stood at $2.0 million in 2023, then slumped by 50.0% to $1.0 million in 2024, then soared by 500.0% to $6.0 million in 2025.
  • The last three Raw Materials figures came in at $6.0 million (Q4 2025), $1.0 million (Q4 2024), and $2.0 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Genmab A 2.05 Bn 548.77 Mn 1.07 Bn

Historic Data

Download Data
DateValue
Dec 31, 2025 6.00 Mn
Dec 31, 2024 1.00 Mn
Dec 31, 2023 2.00 Mn